• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Prospective Data: Breast Cancer Risk and Menopausal Hormone Therapy

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • The Collaborative Group on Hormonal Factors in Breast Cancer (Lancet, 2019) reviewed epidemiologic propective data from multiple sources, both published and unpublished, to determine the relationship between menopausal hormone therapy (MHT) and breast cancer risk

METHODS:

  • From 1992, the Collaboration searched and reviewed potentially eligible epidemiologic studies
    • Eligible epidemiological studies have been sought regularly by computer-aided literature searches, manual searches of review articles, written communications, and discussions at scientific meetings
  • Design
    • Prospective studies | Nested case-control design
    • 4 randomly selected controls per case of invasive breast cancer
    • Matched for age, year of birth, and region
  • Included data
    • Individual participant data
    • Prospective studies with information on the type and timing of MHT use
  • Current MHT users included up to 5 years (mean 1.4 years) after last-reported MHT use
  • All analyses included only postmenopausal women
    • Known age at natural menopause (or at bilateral oophorectomy) or
    • Unknown age at menopause but age ≥55 years
  • Logistic regression used to calculate adjusted risk ratios (RRs)
    • Compared particular MHT groups of MHT users vs never users

RESULTS:

  • 58 studies
    • Cases: 143,887 postmenopausal women with invasive breast cancer
    • Controls: 424,972 without breast cancer
    • Mean age: 50 years at menopause | 50 years at starting MHT
  • All MHT types, except vaginal estrogen, were associated with increased risk for breast cancer
  • Excess risk for breast cancer was evident even during 1 to 4 years
    • Estrogen-progestogen: RR 1.60 (95% CI, 1.52 to 1.69)
    • Estrogen-only: RR 1.17 (95% CI, 1.10 to 1.26)
  • Risk doubled during years 5–14
    • Estrogen-progestogen: RR 2.08 (95% CI, 2.02 to 2.15)
    • Estrogen-only: RR 1.33 (95% CI, 1.28 to 1.37)
  • Regardless of preparation type, risks during years 5–14 of current use were
    • Greater with daily vs less frequent progestogen use
    • Greater for ER-positive tumors than for ER-negative tumors
    • Similar regardless if MHT was started at ages 40–44, 45–49, 50–54, and 55–59 years
    • Reduced if MHT started >60 years  
  • Some excess risk persisted for more than 10 years after cessation of MHT, dependent on duration of use
    • Little excess risk with <1 year of MHT use
  • BMI increased breast cancer risk (ER-positive) for never users but not current users

CONCLUSION:

  • Every MHT type, except vaginal estrogens, was associated with excess breast cancer risks
    • Risk related to duration of use | Greater for estrogen-progestogen vs estrogen-only preparations
  • In developed countries starting at 50 years of age, breast cancer incidence at ages 50–69 years would increase by approximately
    • 1/50 users of estrogen plus daily progestogen preparations
    • 1/ 70 users of estrogen plus intermittent progestogen preparations
    • 1/ 200 users of estrogen-only preparations

Joint Royal College of Obstetricians and Gynaecologists & British Menopause Society statement in response to the Lancet study on HRT use and breast cancer risk

  • Study confirms known, small increased risk of breast cancer
  • The statement makes the following key points

For most women, HRT helps to manage menopausal symptoms and is safe

To put the risk into context, a woman has greater risk of developing breast cancer if she is overweight or obese compared to taking HRT

Women must be aware of the effect of obesity and alcohol which increase the risk of breast cancer and modifies the additional risk of HRT 

Learn More – Primary Sources:

Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence

RCOG/BMS response to Lancet study on HRT use and breast cancer risk

Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Learn More  »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

North American Menopause Society: Hormone Therapy Statement
The WHI Randomized Trials: Is Menopausal Hormone Therapy Associated with Long-Term Mortality?
Is There an Association Between Vaginal Estrogen Use and Risk for Cardiovascular Disease and Cancer?
Does Hormone Therapy in Menopause Impact Mortality?
Current Hormonal Contraception Methods and Breast Cancer Risk: Prospective Cohort Data

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site